Cargando…
Evaluation of HOXB13 as a molecular marker of recurrent prostate cancer
Many patients with prostate cancer have disease recurrence following surgical removal of tumors and fail to respond to androgen ablation therapy. Despite the existence of a number of clinical/pathological factors, it is not possible to predict which patients will fall into this category. The results...
Autores principales: | JEONG, TAE-O, OH, KYUNG-JIN, NGUYEN, NGUYEN THI XUAN, KIM, YOUNG-RANG, KIM, MIN SOO, LEE, SANG DON, RYU, SOO BANG, JUNG, CHAEYONG |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493085/ https://www.ncbi.nlm.nih.gov/pubmed/22293681 http://dx.doi.org/10.3892/mmr.2012.769 |
Ejemplares similares
-
HOXB13 promotes androgen independent growth of LNCaP prostate cancer cells by the activation of E2F signaling
por: Kim, Young-Rang, et al.
Publicado: (2010) -
HOXB13 is co-localized with androgen receptor to suppress androgen-stimulated prostate-specific antigen expression
por: Kim, Sin Do, et al.
Publicado: (2010) -
Differential CARM1 expression in prostate and colorectal cancers
por: Kim, Young-Rang, et al.
Publicado: (2010) -
HOXB13 mutations and prostate cancer in Poland
por: Kluźniak, Wojciech, et al.
Publicado: (2012) -
Oncogenic mechanisms of HOXB13 missense mutations in prostate carcinogenesis
por: Cardoso, Marta, et al.
Publicado: (2016)